Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ACS Announces New Editor-in-Chief of Chemical Research in Toxicology

Published: Friday, July 20, 2012
Last Updated: Friday, July 20, 2012
Bookmark and Share
Stephen S. Hecht will take over as Editor-in-Chief of Chemical Research in Toxicology in January 2013.

The American Chemical Society (ACS) has announced that Stephen S. Hecht, Ph.D., will take over as Editor-in-Chief of Chemical Research in Toxicology in January 2013.

Hecht is the Winston R. and Maxine H. Wallin Land Grant Professor of Cancer Prevention and American Cancer Society Professor at the Masonic Cancer Center at the University of Minnesota, Minneapolis, and currently serves as an Associate Editor of the Journal of Medicinal Chemistry.

Hecht will succeed Lawrence J. Marnett, Ph.D., who will retire from the journal at the end of this year.

Marnett, Mary Geddes Stahlman Professor of Cancer Research and professor of biochemistry, chemistry and pharmacology at Vanderbilt University, has served as Editor-in-Chief of Chemical Research in Toxicology since he helped found the journal in 1988.

Marnett will assist with the transition and remain with the journal in his current role through the end of 2012.

“Professor Hecht’s distinguished career, his experience in both chemical toxicology and medicinal chemistry and his vision for the future of the journal will serve him well as the editor of Chemical Research in Toxicology,” said Susan King, senior vice president of the Journals Publishing Group at ACS.

Hecht, elected an ACS Fellow in 2009, received his B.S. in chemistry from Duke University in 1964 and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology in 1968.

He joined the Masonic Cancer Center in 1996, where his research interests center on elucidating the mechanisms of chemical carcinogenesis in humans, including those related to tobacco-induced cancer.

His group looks for carcinogen biomarkers and applies them to molecular epidemiology and cancer prevention, and more specifically, to the prevention of lung and esophageal cancer.

Outgoing Editor Marnett said of Hecht, “He is the second-leading author over the past 25 years of all the authors who have published in the journal. His work is very high quality, very rigorous and very chemical. He appreciates what the journal has meant in the community, and I know he’s very interested in seeing it flourish.”

Hecht has received numerous awards, including the Joseph Cullen Award from the American Society of Preventive Oncology in 2012, the Founders’ Award from the ACS Division of Chemical Toxicology in 2009 and the American Association for Cancer Research-Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research in 2006.

Chemical Research in Toxicology publishes new and original research on the chemical basis of toxic responses in living organisms.

That research includes how cells and organisms respond to chemical or biological toxic agents and how those agents can lead to disease.

Chemical Research in Toxicology received 10,444 total citations in 2011. The journal also has a high Impact Factor of 3.779, as reported by the 2011 Journal Citation Reports® (Thomson Reuters, 2012).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!